XmAb18087

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instanceOf monoclonal antibody
gptkbp:administrativeDivision infusion
every 2 weeks
gptkbp:analyzes cancer patients
gptkbp:barrelLength high
gptkbp:clinicalTrials gptkb:United_States
gptkb:Xencor
Phase 1
pending
Phase 2
open-label study
gptkbp:collaborations various research institutions
gptkbp:community_service overall survival
progression-free survival
safety and tolerability
gptkbp:compatibleWith immune modulation
gptkbp:contraindication gptkb:melanoma
renal cell carcinoma
non-small cell lung cancer
gptkbp:currentStatus completed
gptkbp:developedBy gptkb:Xencor
gptkbp:dosageForm weight-based dosing
gptkbp:evaluates under investigation
gptkbp:formulation liquid
gptkbp:hasPopulation advanced cancer patients
gptkbp:historicalResearch recombinant DNA technology
https://www.w3.org/2000/01/rdf-schema#label XmAb18087
gptkbp:market high
gptkbp:patentAssignee gptkb:Xencor,_Inc.
gptkbp:patentStatus patented
gptkbp:productionCompany clinical trials
gptkbp:purpose cancer immunotherapy
gptkbp:regulatoryCompliance investigational new drug
gptkbp:relatedTo immune system
gptkbp:releaseYear 2015
gptkbp:research public and private sources
biopharmaceutical research
gptkbp:research_areas monoclonal antibodies
immunotherapy
gptkbp:researchAndDevelopment quality of life improvement
tumor shrinkage
improved immune response
prolonged survival
biomarker_identification
gptkbp:researchFocus oncology
gptkbp:researchInterest academic institutions
peer-reviewed journals
gptkbp:route intravenous
gptkbp:safetyFeatures under evaluation
gptkbp:sideEffect immune-related adverse events
gptkbp:status in development
gptkbp:storage refrigerated
gptkbp:targets T cells
PD-1
PD-1 pathway inhibition
various solid tumors
gptkbp:triggerType immune checkpoint inhibition
blocks PD-1 receptor
gptkbp:usedFor cancer treatment